Author Affiliations: Center for Neurologic Diseases, Department of Neurology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Mass.
An explosion of new techniques to explore DNA and protein biology during the last 2 decades has illuminated one of the most enigmatic and intractable subjects in biomedicine—neurodegeneration. Eponymic diseases of the nervous system that were until recently characterized by mechanistic ignorance and therapeutic nihilism are falling steadily to the power of molecular genetics, cell biology, biochemistry, and animal modeling. Alzheimer, Huntington, Creutzfeld-Jacob, and Parkinson diseases, as well as amyotrophic lateral sclerosis, spinocerebellar atrophies, frontotemporal dementia, and other previously obscure diseases, have all yielded rapid progress in the deciphering of their biochemical pathology and genetic underpinnings. This sea change in our understanding of a group of incurable diseases that confer enormous personal and societal burdens has brought us to the verge of rationally designed therapies and, in some cases, into actual human trials.
Perhaps the foremost example, both in terms of its impact on society and how far we have moved toward clinical application, is that of Alzheimer disease (AD). This most common of the late-life dementias is rising in prevalence with the aging of populations in developed countries and may now affect 20 to 30 million people worldwide. I will review the classic neuropathological lesions of AD that, despite some doubts along the way, turned out to provide a road map to the etiology and pathogenesis of the disease. Then, I will discuss how elucidating the genotype-to-phenotype relationships of certain genetic alterations linked to familial forms of AD has pinpointed molecular targets for treatment and prevention, some of which are now being addressed in clinical trials.
The successful attempts during the mid-1980s to develop methods for purifying microvascular and plaque amyloid deposits and neurofibrillary tangles from postmortem brains have enabled much of the further progress in this field. In particular, the isolation and partial sequencing of the amyloid β-protein (Aβ) by Glenner and Wong,1 followed by the recognition that amyloid plaques (but not neurofibrillary tangles) were composed of the same protein, led to the cloning of the β-amyloid precursor protein (APP) and the localization of its gene to human chromosome 21.2 The latter finding offered an explanation for the invariant development of the neuropathology of AD (often accompanied by cognitive decline) in patients with trisomy 21 (Down syndrome). It soon became clear that patients with Down syndrome begin to show immature Aβ deposits, known as diffuse plaques, as early as the second decade of life and later develop mature neuritic (amyloid) plaques and neurofibrillary tangles indistinguishable from those found in patients with AD. This information provided the first genetic evidence that Aβ build-up can precede and apparently initiate the typical neuropathology of AD. It was subsequently discovered that Aβ is naturally produced by all cells throughout life,3 namely through the sequential cleavage of APP by 2 proteases nicknamed β-secretase and γ-secretase (Figure).
The proteolytic processing of β-amyloid precursor protein (APP) and the fate of amyloid β-protein.
Separate studies established the nature of the neurofibrillary tangles, namely that they consist of paired helical and straight cytoplasmic filaments composed of highly phosphorylated forms of the microtubule-associated protein tau.4 As in the case of identifying Aβ in plaques, the discovery of tau as the principal component of tangles made it possible to link these protein abnormalities to the genetics of familial forms of AD.
The hypothesis that AD represents an amyloidosis of the brain (ie, that the disease is caused by the gradual build-up and aggregation of Aβ) preceded the first genetic discoveries in the disease and helped direct the search for causative genes. In accord, the first AD-causing gene to be identified was APP, in which dominantly inherited mutations lead to an early and aggressive form of the disease.5 As many as 20 APP missense mutations are now known, and they all cluster at or near the sites in the precursor that are cleaved by the β-, γ- or α-secretases.6 Next, the ε4 allele of apolipoprotein E was identified as a major genetic risk factor for conventional (late-onset) AD, after the apolipoprotein E protein (apoE) in human cerebrospinal fluid was found to bind specifically to immobilized Aβ peptide.7 Genetic epidemiology has robustly confirmed an enhanced risk for developing AD in patients with 1 or 2 ε4 alleles who are in their sixth and seventh decade of life. Subsequently, elegant experiments in apoE knockout and transgenic mouse models showed that the presence of the apoE4 protein markedly increases the amount of fibrillar Aβ deposits in the brain compared with the effects of the apoE3 protein.8
The next 2 AD genes discovered were presenilin (PS) 1 and PS2.9,10 More than 140 known missense mutations in PS1 and roughly 10 in PS2 confer an aggressive, early-onset phenotype. In cell culture, transgenic mouse models, and the sera and brains of affected patients, it has been shown that PS1 and PS2 missense mutations increase the production of Aβ42, the highly self-aggregating 42-residue form of Aβ, often at the expense of the more commonly produced 40-residue form.11 The mutations do so because PS is the catalytic subunit of γ-secretase, an unusual intramembrane-cleaving aspartyl protease.12 Mutations causing AD alter the conformation of PS, apparently enhancing coordination between the 2 catalytic aspartates and the Aβ 42-43 peptide bond in the transmembrane domain of APP. The identification of PS as the active site of γ-secretase provides a linchpin for the amyloid hypothesis of AD: all of the mutations currently known to cause autosomal dominant AD occur either in the substrate (APP) or the protease (PS) of the reaction that produces Aβ.
Several other candidate genes are in the process of being definitively confirmed as predisposing to late-onset AD. Ultimately, a variety of genes will probably be determined to confer risk, each one responsible for only a relatively small fraction of all cases.
The long-standing debate about the primacy of tangles vs plaques in AD pathogenesis has been largely resolved by the exciting discovery of missense and splicing mutations in tau, the subunit of the neurofibrillary tangles. The phenotypes associated with the inheritance of tau mutations to date include frontotemporal dementia with parkinsonism, progressive supranuclear palsy, and Pick disease, but not AD. This knowledge indicates that a primary alteration of tau can cause severe neuronal degeneration, profound dementia, and the death of the host in the absence of Aβ deposition. Alzheimer disease is defined neuropathologically by the presence of both plaques and tangles, but the accumulation of tangles cannot by itself explain the development of Aβ deposits in this disease. Indeed, studies in double transgenic mice suggest that the presence of Aβ-elevating APP mutations augments the formation of tau deposits in neurons, rather than the converse.13 The precise way in which Aβ accumulation induces a cascade of neuronal metabolic changes that includes the hyperphosphorylation of wild-type tau molecules in AD is a subject of active study, and several kinases have been proposed as culprits.
Although numerous aspects of the detailed mechanism of neuronal dysfunction in AD remain unsettled, a broad consensus about some of the principal pathogenic events has been reached by many investigators in the field. Evidence from genetic, neuropathological, cell biology, and animal modeling studies suggests that the gradual accumulation of Aβ42 in limbic and association cortices leads to its aggregation into oligomers, polymers, and amyloid fibrils. These various assemblies—in particular, small diffusible oligomers—appear to be able to induce synaptic and dendritic dysfunction and to activate microglia and astrocytes (representing a local inflammatory reaction). Such changes, first subtle and then increasingly robust, are accompanied by an array of further cellular and biochemical alterations, including altered ionic homeostasis, free radical formation, oxidative injury, neuritic dystrophy, and, ultimately, neuronal death. Because the potential cellular responses to Aβ are myriad and complex, it has been argued that it would be more efficient to decrease the levels of Aβ42 in the brain than to attempt to interfere with 1 or more of these secondary effects of Aβ.
While intensive research into AD pathogenesis has occurred in large part in academic laboratories and enabled the field to move toward therapy, the actual discovery, preclinical validation, and clinical development of agents that lower Aβ are being conducted primarily by biotechnology and pharmaceutical companies. Indeed, the movement from basic research to the identification of treatments represents an important cooperative interaction between these 2 sectors. Many companies are now vigorously pursuing several well-defined molecular targets, the inhibition of which could allow not only treatment of active AD but perhaps also its prevention.
Based on the information reviewed herein, there is great interest in identifying small-molecule inhibitors of the β- and γ-secretases. The availability of a crystal structure for the active site of β-secretase (also known as BACE-1)14 is enabling medicinal chemists to systematically modify inhibitors arising from initial compound screens in ways that should enhance potency and still ensure specificity. Because genetic deletion of the BACE-1 gene in mice appears to have little or no adverse consequences, β-secretase inhibitors would be expected to have few mechanism-based adverse effects. Therefore, β-secretase inhibition represents a particularly attractive therapeutic target. On the other hand, the size and shape of the active site of this aspartyl protease present considerable challenges for the design of potent small-molecule inhibitors that can also achieve good brain penetration.
In the case of γ-secretase, the situation is more complex. Because its active site is intramembranous, and because PS requires 3 additional membrane proteins (nicastrin, Aph-1, and Pen-2) for proteolytic activity, the possibility of crystallizing γ-secretase is highly remote. Moreover, this unusual enzyme has numerous substrates besides APP, perhaps the most important of which is Notch. Notch comprises a family of cell-surface receptors that must undergo intramembranous cleavage by PS/γ-secretase to mediate cellular differentiation in multicellular organisms. Notch processing is thus required for life. It remains to be seen whether γ-secretase inhibitors can be found that lower the cleavage of APP to hinder sufficiently the release of Aβ but do not interfere with Notch cleavage to an extent that would produce adverse effects. Intriguingly, there is evidence that certain nonsteroidal anti-inflammatory drugs such as ibuprofen may subtly modulate γ-secretase cleavage to lower Aβ42 production without impairing Aβ40 production and Notch cleavage.15 Derivatives of certain anti-inflammatory drugs that can no longer inhibit cyclooxygenase activity but still lower Aβ42 production are currently being tested in patients with AD.
A different treatment approach to the Aβ problem in AD is to prevent the aggregation of the peptide and/or promote its clearance. One novel paradigm that appears to work by the latter mechanism is anti-Aβ immunotherapy.16 Two general approaches have been studied in AD mouse models: active vaccination with Aβ or fragments thereof and passive infusions of monoclonal antibodies to Aβ. Both have worked well to clear plaques and lower Aβ levels in mice, and they have decreased neuritic dystrophy and even ameliorated learning deficits in these models. A clinical trial of active vaccination with Aβ42 peptide plus an adjuvant led to the development of meningoencephalitis (apparently mediated by anti-Aβ T cells) in 18 (6%) of 300 study patients after just 2 vaccinations. Administration of the vaccine was halted, but all patients were followed up closely, and the 18 patients recovered to baseline status. Neuropsychological evaluations after 1 year suggested that some of the vaccine recipients had experienced stabilization of their cognitive decline and perhaps even some improvement on some measures of cognition regardless of whether they had experienced the adverse T-cell reaction—and this was correlated with their titers of anti-Aβ antibodies.17 Moreover, when study patients died of causes other than AD, a few autopsies revealed an apparent partial clearing of Aβ deposits in some cortical regions. All of this new knowledge has led to the continuation of the immunotherapy approach in a new phase 1 trial, this time in the form of passive administration of a humanized monoclonal antibody to Aβ. An alternative active approach that may carry a lower risk of adverse events is mucosal (nasal or oral) vaccination. This method has been tried in APP transgenic mice (but not in humans) and has led to significant decreases in plaque burden, Aβ levels, neuritic dystrophy, and gliosis.18
There are, of course, numerous other prospective strategies to treat or prevent AD, including some directed against the amyloid problem (eg, antiaggregation compounds and metal chelators) and some directed against other features of pathogenesis (eg, neurotrophins, antioxidants, and free radical scavengers). But anti-Aβ immunotherapy represents the most advanced disease-modifying attempt so far, in terms of experience in humans. All of the various thrusts toward treatment and prevention should be pursued vigorously by both academic and biopharmaceutical investigators so that more than 1 approach ultimately becomes available for clinical use.
In the future, it is likely that middle-aged adults will commonly undergo a formal risk assessment for AD that will include detailed family history taking, brief neuropsychological assessment, screening for known genetic risk factors, measurements of plasma Aβ (and perhaps cerebrospinal fluid Aβ and tau), and quantitative assessment of brain β-amyloid burden by imaging procedures.19 Based on the results, patients would be offered 1 of the potentially disease-slowing therapies contemplated herein or others not discussed here. One can only hope that such a scenario comes into practice well before another generation of older humans succumbs to this devastating disease.
Correspondence: Dennis J. Selkoe, MD, Center for Neurologic Diseases, Department of Neurology, Brigham and Women’s Hospital and Harvard Medical School, 77 Louis Pasteur Ave, Seventh Floor, Boston, MA 02115.
Accepted for Publication: August 17, 2004.
Financial Disclosure: Dr Selkoe is a founding scientist of Athena Neurosciences and a consultant to Elan Corp.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Neurology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 80
Customize your page view by dragging & repositioning the boxes below.
Users' Guides to the Medical Literature
Users' Guides to the Medical Literature
All results at
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.